The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors

被引:13
作者
Shen, Xianjuan [1 ]
Wang, Mei [2 ]
Guo, Yuehua [2 ]
Ju, Shaoqing [1 ]
机构
[1] Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Nantong, Peoples R China
[2] Nantong Univ, Med Off, Nantong, Peoples R China
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 25卷 / 05期
关键词
BAFF; RFQ-PCR; NHL; BAFF; STIMULATOR; BLYS;
D O I
10.17219/acem/29182
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Lymphoma is a malignant tumor of the immune system originating from lymph nodes and extra-lymphatic tissues. Its occurrence is believed to be associated with various immune cells due to the proliferation and differentiation of lymphocytes during the immune response. It has been found in many studies that B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) superfamily, could specifically activate B lymphocytes and promote their proliferation. Objectives. To explore correlations between non-Hodgkin lymphoma (NHL) and the expression of BAFF and its receptors in NHL patients. Material and Methods. The protein expression of BAFF and its receptors in serum and BAFF mRNA expression in peripheral blood mononuclear cells (PBMCs) of 47 NHL patients and 20 healthy subjects were detected by ELISA and RFQ-PCR and compared with LDH and beta(2) M levels. Results. BAFF mRNA expression in the PBMCs of NHL patients was significantly higher than in healthy controls. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in NHL patients were significantly higher than in healthy controls, and were not significantly correlated with beta(2) M and LDH levels. Conclusions. The serum protein concentration of BAFF and the expression level of BAFF mRNA in PBMCs of NHL patients underwent abnormal changes, indicating that BAFF and its receptors may play some role in the pathogenesis of NHL
引用
收藏
页码:837 / 844
页数:8
相关论文
共 50 条
  • [21] Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma
    Lievin, Raphael
    Hendel-Chavez, Houria
    Balde, Aliou
    Lancar, Remi
    Algarte-Genin, Michele
    Krzysiek, Roman
    Costagliola, Dominique
    Assoumou, Lambert
    Taoufik, Yassine
    Besson, Caroline
    [J]. CANCERS, 2022, 14 (01)
  • [22] The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis
    Peveling-Oberhag, J.
    Arcaini, L.
    Bankov, K.
    Zeuzem, S.
    Herrmann, E.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2016, 23 (07) : 536 - 544
  • [23] Correlation of B-cell-activating Factor Levels and Diseases Activity in Systemic Lupus Erythematosus Patients
    Vitri, Ria Yolanda
    Wachjudi, Rachmat Gunadi
    Ghassani, Nadia Gita
    Hamijoyo, Laniyati
    [J]. INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (01) : 13 - 17
  • [24] Elevated serum levels of B-cell activating factor in pediatric renal transplant patients
    Anja Lehnhardt
    Franziska Dunst
    Michael van Husen
    Sebastian Loos
    Jun Oh
    Thomas Eiermann
    Martina Koch
    Markus J. Kemper
    [J]. Pediatric Nephrology, 2012, 27 : 1389 - 1395
  • [25] Cerebrospinal fluid B-cell activating factor levels as a novel biomarker in patients with neurosarcoidosis
    Sumi, Kaori
    Masuda, Teruaki
    Kimura, Noriyuki
    Akiyoshi, Yuko
    Obayashi, Konen
    Matsubara, Etsuro
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 449
  • [26] B-Cell Activating Factor Levels in Rheumatoid Arthritis Patients in Response to Treatment with Biologics
    Pyrpasopoulou, Athina
    Balaska, Ekaterini
    Triantafyllou, Areti
    Anyfanti, Panagiota
    Aslanidis, Spyros
    Douma, Stella
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2012, 32 (07) : 338 - 340
  • [27] High B-cell activating factor levels in multi-transfused thalassemia patients
    Watanaboonyongcharoen, Phandee
    Akkawat, Benjaporn
    Tohthong, Thanida
    Rojnuckarin, Ponlapat
    [J]. TRANSFUSION MEDICINE, 2021, 31 (05) : 350 - 356
  • [28] Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren’s Syndrome-Associated B-Cell Non-Hodgkin’s Lymphoma
    J. Carbone
    R. Perez-Fernandez
    A. Muñoz
    P. Sabin
    L. Carreño
    E. Fernandez-Cruz
    [J]. Clinical Reviews in Allergy & Immunology, 2008, 34 : 80 - 84
  • [29] Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Shi, Rong
    Lu, Tong
    Ku, Grace
    Ding, Hao
    Saito, Tomohisa
    Gibiansky, Leonid
    Agarwal, Priya
    Li, Xiaobin
    Jin, Jin Yan
    Girish, Sandhya
    Miles, Dale
    Li, Chunze
    Lu, Dan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (03) : 347 - 359
  • [30] Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B-cell non-Hodgkin lymphoma in LMIC setting
    Radhakrishnan, Venkatraman
    Kritthivasan, Venkatakrishnan
    Kothandan, Balaji Thiruvengadam
    Srinivasan, Prasanth
    Das, Gargi
    Ramamurthy, Jaikumar
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 (12)